J&J rounds out the year with twin buyouts, gaining control of delivery and surgical robotics tech
J&J is scooping up one of Bristol-Myers-Squibb’s biotech partners specialized in bladder biology, with a particularly keen interest in a technology that releases cancer drugs locally.
The pharma giant isn’t looking to make a splash here — the financial terms remain undisclosed — but they are clear that they see a potential for Taris’ silicone-based drug delivery device far beyond bladder cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.